ECR 2022

iBiopsy®’s Median team will be exhibiting at the ECR on July 13-17, in Vienna. Meet us at booth #AI-29, we will be presenting the latest updates of iBiopsy®, our unique end-to-end AI/ML tech_based Software as Medical Device (SaMD).

Schedule a meeting

Median's latest news

Fredrik Brag, CEO and founder of Median, provides additional insights on iBiopsy ® Lung Cancer Screening CADe/CADx Software as Medical Device (in French).

Watch video

Latest press releases

13 June 2022

Bryan Garnier & Co initiates the coverage of Median Technologies with a “Buy” recommendation

In the initiation report published on June 10, 2022, Bryan Garnier & Co initiates the coverage of the stock with a buy recommendation and values the company at 40 euros per share.

2 June 2022

Median Technologies to present an abstract at the 2022 ASCO Annual Meeting, June 3 – 7, 2022, McCormick Place, Chicago, IL, USA

Median Technologies (ALMDT) announced today that it will be presenting an abstract at the 2022 ASCO Annual Meeting, June 3-7, McCormick Place, Chicago, IL, USA (exhibition dates: June 4-6).

31 May 2022

Median Technologies launches Imaging Lab, spearheading the integration of iBiopsy® Artificial Intelligence technologies into iCRO imaging services for oncology trials

With Imaging Lab, Median will provide biopharmaceutical companies with new decision-making tools for clinical trials by leveraging images with data mining and Artificial Intelligence (AI) technologies from iBiopsy® and radiomics. Imaging Lab’s solutions will support the pharmaceutical industry’s paradigm shift towards therapies targeting patients with early-stage cancers. The Imaging Lab team will be exhibiting at the ASCO Annual Conference in Chicago, June 3-7, 2022, Median’s booth #2098.

23 May 2022

Median Technologies announces the availability of the preparatory documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 14, 2022

The shareholders of Median Technologies (ALMDT:PA) are invited to participate at the Shareholders’ Ordinary and Extraordinary General Meeting which will be held on Tuesday June 14, 2022, at 5:00 PM at PDGB, 174 avenue Victor Hugo – 75116 Paris.

5 May 2022

Median Technologies is moving forward with the FDA interactions for its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Median has received the FDA’s feedback following the 513(g) regulatory submission for its iBiopsy® LCS CADe/CADx Software as Medical Device. Median will proceed through a 510(k) submission to obtain an FDA device clearance and market authorization, targeted for end 2023. On May 2, 2022, Median initiated a Q-submission process, composed of several submissions, to request feedback from the FDA on various topics such as the pivotal study protocols.


Our Winter Corporate Newsletter

We are pleased to share with you our Winter Corporate Newsletter, presenting our most recent announcements and what we did during the fourth quarter of 2021 and in early Q1 2022. Click below to read the Newsletter!


JUNE 21st, 2022

Overcoming the challenges in deploying new imaging biomarkers in clinical trials – Perspectives from patients, physicians and other stakeholders

This webinar is jointly organized by Labcorp Drug Development and Median Technologies. New Imaging biomarkers have a strong potential to provide additional insight for clinical trials: better selection of patients, prediction of response to therapy, early assessments of drug effects and safety. However, implementing them in clinical trials often promote challenges.

The aim of this webinar is to discuss these challenges from the perspective of patients, physicians and the different stakeholders involved in the oncology clinical trials. Want to know more? Register now!

Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Read more


Enhancing imaging diagnostic accuracy

Our team of data scientists, AI engineers and clinicians is focused on developing the most accurate and cutting-edge AI-powered Software as a Medical Device (SaMD). iBiopsy® targets: lung cancer, liver cancer, and NASH to provide to patients an earlier and optimal diagnosis avoiding unnecessary invasive tests.

Read more


Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Stock Market Data

Get in touch

Together, let's build the future of medicine

Contact us Jobs at Median